Enanta Pharmaceuticals Inc Stock Price, News & Analysis

Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated a Phase 2b study to assess the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults at high risk of complications from acute respiratory syncytial virus (RSV) infection. The study will involve approximately 180 participants treated with EDP-938 or placebo over 5 days, with evaluations made for 28 days post-treatment. Previous studies indicated EDP-938's ability to significantly reduce RSV RNA levels and its favorable safety profile, supporting its potential for optimal clinical benefit.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data on EDP-323, a novel non-nucleoside RSV L-inhibitor, and advancements in virology methods for RSV and hMPV research. Presented at the 12th International RSV Symposium, EDP-323 showed potent inhibition of RSV replication in various models, including a mouse infection model that demonstrated improved lung histopathology. The company's research is supported by royalties from its collaboration with AbbVie on hepatitis C treatments, aiding the advance of its pipeline for respiratory viral infections.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced new preclinical data for its respiratory syncytial virus (RSV) program, set to be presented at the 12th International RSV Symposium from September 29 to October 2, 2022, in Belfast, UK. Highlights include an oral presentation titled “EDP-323, a Novel L-Protein Inhibitor, for the Treatment of RSV” scheduled for October 1, and multiple poster presentations on September 30. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from hepatitis C virus products.

Enanta Pharmaceuticals (NASDAQ:ENTA) announced new preclinical data for EDP-235, its oral coronavirus protease inhibitor aimed at treating COVID-19, to be presented at IDWeek 2022 from October 19-23, 2022, in Washington, DC. An oral presentation is scheduled for October 21, 2022, at 12:15 PM ET, discussing EDP-235's potential to mitigate cytokine storms in high-risk COVID-19 patients. Enanta continues its focus on small molecule drugs for viral infections and liver diseases, supported by royalties from its collaboration with AbbVie on hepatitis C virus products.

Enanta Pharmaceuticals (NASDAQ: ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, will feature CEO Jay R. Luly, Ph.D., at two investor conferences in September 2022. He will present at the Wells Fargo Healthcare Conference on September 8 at 3:10 p.m. ET, followed by a fireside chat at the Baird Global Healthcare Conference on September 13 at 9:40 a.m. ET. Live webcasts will be available on Enanta’s website, with replays accessible for 30 days after the events.

Enanta Pharmaceuticals reported fiscal Q3 2022 revenue of $19.5 million, primarily from royalties on AbbVie's MAVYRET®, a decline from $21.6 million in Q3 2021. R&D expenses decreased to $39.1 million from $47.0 million, while G&A expenses rose to $12.9 million from $8.5 million. The net loss was $31.7 million ($1.53 per share), compared to $24.0 million ($1.19 per share) in the previous year. Enanta plans to initiate Phase 2 studies for its COVID-19 treatment EDP-235 and RSV treatment EDP-938 in Q4 2022.

Enanta Pharmaceuticals, a clinical-stage biotechnology company, appointed Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer on August 8, 2022. Dr. Rottinghaus brings over 20 years of drug development experience, notably leading clinical programs at Alexion and Pfizer. His expertise will support Enanta's ongoing clinical programs, including a Phase 2 study on COVID-19 and advancements in respiratory syncytial virus (RSV). This appointment aims to further Enanta's goal of becoming a leader in antiviral treatments.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is set to announce its financial results for Q3 2022, concluded on June 30, 2022, on August 8, 2022, post-market. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and updates on the company’s R&D pipeline. Enanta focuses on drug discovery for viral infections and liver diseases, including respiratory syncytial virus (RSV) and hepatitis B virus (HBV), while funding is supported by royalties from its collaboration with AbbVie on hepatitis C virus (HCV) treatments.

Enanta Pharmaceuticals (NASDAQ: ENTA) announced positive topline data from a Phase 1 study of EDP-235, a coronavirus 3CL protease inhibitor. The study showed EDP-235 was generally safe and well-tolerated at doses up to 400mg. Plasma drug levels exceeded the EC₉₀ by up to 12-fold for the Delta variant. Preclinical data indicated significant lung tissue distribution, making it a candidate for once-daily oral treatment against COVID-19 variants. Enanta plans to initiate a Phase 2 study in 4Q 2022, pending FDA review.